Industry news

• 'Pharma Clinical Trial Services Market Will Reach $30.6 Billion in 2015' Predicts New Visiongain Report

  04 February 2013

  A new report by Visiongain predicts that the world market for pharma clinical trial services will be worth $30.6bn in 2015. Between 2011 and 2017, the global market will grow with a high single digit CAGR. Demand for late phase trial services will drive growth to 2023. Those findings appear in Pharma Clinical Trial Services: World Market 2013-2023, published in January 2013. Growth for these CROs will be focused on building upon the service portfolio in these markets, as well as entering new emerging markets in Asia, Latin America and Central and Eastern Europe.

• Russian Pharmaceutical Industry toward Innovation: moving from "Made in Russia" to "Invented in Russia"

  30 January 2013 Modern Russia

  In the past years, the global pharmaceutical industry has been experiencing a shift in its development: a geographic swing away from the major mature markets, to a set of new dynamics in “pharmerging” countries. The Russian pharmaceutical market is one of these most dynamic and rapidly growing markets.

• Pharmaceutical Promotional Spending: Global Trends

  18 January 2013 Christopher Wooden/ Cegedim Strategic Data

  In the twelve-month period to June 2012, industry spending on audited channels came to $90 billion in constant US Dollars with spending in the United States accounting for 32% of the worldwide total. Significant increases in emerging markets ( Brazil +22%, Russia +42% , China +30%) were in marked contrast to cuts in more established markets (USA -6%, EU5 -3.6%). 

• Big pharma emerging mkts tactics shift as growth slows

  18 January 2013 Deena Beasley/ Thomson Reuters

  Major pharmaceutical companies aiming to jumpstart growth by investing in emerging markets are reassessing strategies after less-than-stellar results in 2012.  New tactics are expected to include more joint ventures where risks are shared with local partners.

   

• San Diego Life Sciences Roundup: Trius, CoDa, Zacharon, & More

  09 January 2013 Bruce V. Bigelow, Xconomy

  The annual International CES in Las Vegas again featured a Digital Health Summit, which included a number of San Diego-based startups. Rick Valencia of Qualcomm Life posted an interesting blog here, and an end-of-year report from Rock Health showed that investments in digital health startups increased more than 44 percent in 2012, to $1.4 billion from $968 million in 2011.

• Russia sets out limits to purchasing imported meds

  04 January 2013 Tracy Staton, PharmaTimes Online

  Russia's government is set to limit state purchasing of pharmaceuticals from overseas, following the country's accession to the World Trade Organisation (WTO), according to local reports.

• Venture Capital, Russian Style

  20 December 2012 Katya Soldak, Forbes

  Russia’s scientific community may have experienced a “brain drain” over the past twenty years but the fundamentals of the famous soviet science are still in place, and Putin’s government is revitalizing science-based industry. Betting on nanotechnology, companies can potentially generate substantial returns. Enter Rusnano, a venture capital fund with plans to become a player in the global capital market.

• Tough Prescription: Drug Industry Faces Modernization

  18 December 2012 Irina Filatova, The Moscow Times

  Only a fraction of medicines bought in Russia are made here, and Russian drug companies are few. Dragging the pharmaceutical industry into the 21st century will require investment from foreign companies - and from the government, experts say.

• Abundant Opportunities within the Russian OTC Market, Invest with Caution when Making the Switch, Suggests Kline

  05 December 2012 PRNewswire

  Russia's rapidly growing over-the-counter market, posting a 12% increase to reach RUB 480 billion (USD 16.4 billion) at the manufacturers' level in 2011, holds much potential for pharmaceutical companies. Although a slight decrease in growth was observed against the previous year, according to new analysis Emerging Markets Rx-to-OTC Switch: Forecasts and Opportunities by global consulting and research firm Kline & Company, the Russian market remains highly robust compared to the U.S. market's 2.4% growth and comparable with the neighboring emerging market of China posting 15.0%.

• Russian pharmaceutical market developing

  30 November 2012 Jim Butschli, Healthcare Packaging

  Investments from its government and the international community continue; meanwhile, unhealthy lifestyles contribute to greater need for medications.